Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 10/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 10/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.45 |
| ▸ | CFTR | P13569 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | QPCT | Q16769 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909859 | 0.94 | PIK3CD (0.67) | PIK3CAPIK3CDPIK3CBPIK3CGCSNK2A2 | |
| SCHEMBL910336 | 0.85 | PIK3CD (0.67) | PIK3CAPIK3CDPIK3CBPIK3CGCSNK2A2 | |
| Alcohol SCHEMBL6005491 | 0.83 | PIK3CD (0.56) | PIK3CAPIK3CDPIK3CBPIK3CGCSNK2A2 | |
| SCHEMBL12904313 | 0.79 | PIK3CD (0.56) | PIK3CAPIK3CDPIK3CBPIK3CGCSNK2A2 | |
| SCHEMBL910015 | 0.77 | PIK3CD (0.57) | PIK3CAPIK3CDPIK3CBPIK3CGCSNK2A2 | |
| SCHEMBL909736 | 0.77 | PIK3CD (0.60) | PIK3CAPIK3CDPIK3CBPIK3CGCSNK2A2 | |
| SCHEMBL6132108 | 0.77 | PIK3CD (0.52) | PIK3CAPIK3CDPIK3CBPIK3CGCSNK2A2 | |
| SCHEMBL909694 | 0.76 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGCSNK2A2 | |
| SCHEMBL30002937 | 0.76 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGCSNK2A2 | |
| SCHEMBL909882 | 0.74 | PIK3CA (0.68) | PIK3CAPIK3CDPIK3CBPIK3CGCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | PI4KA, PI4KB, PI4K2B | PIK3CA 16/4885PIK3CD 15/4885PIK3CB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.